[go: up one dir, main page]

MX2019007352A - Amino acid compositions and methods for the treatment of muscle diseases and disorders. - Google Patents

Amino acid compositions and methods for the treatment of muscle diseases and disorders.

Info

Publication number
MX2019007352A
MX2019007352A MX2019007352A MX2019007352A MX2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A MX 2019007352 A MX2019007352 A MX 2019007352A
Authority
MX
Mexico
Prior art keywords
amino acid
methods
disorders
treatment
acid compositions
Prior art date
Application number
MX2019007352A
Other languages
Spanish (es)
Inventor
Afeyan Raffi
Hamill Michael
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of MX2019007352A publication Critical patent/MX2019007352A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This disclosure provides compositions comprising amino acid entities. The disclosure also provides methods for enhancing muscle function comprising administering an effective amount of the compositions to a subject in need thereof.
MX2019007352A 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of muscle diseases and disorders. MX2019007352A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US201762491776P 2017-04-28 2017-04-28
US201762545358P 2017-08-14 2017-08-14
US201762576321P 2017-10-24 2017-10-24
PCT/US2017/067368 WO2018118957A1 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of muscle diseases and disorders

Publications (1)

Publication Number Publication Date
MX2019007352A true MX2019007352A (en) 2019-09-05

Family

ID=61025047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007352A MX2019007352A (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of muscle diseases and disorders.

Country Status (21)

Country Link
US (3) US20180207119A1 (en)
EP (1) EP3554493A1 (en)
JP (1) JP2020502183A (en)
KR (1) KR20190099243A (en)
CN (1) CN110267655A (en)
AU (1) AU2017379825A1 (en)
BR (1) BR112019012476A2 (en)
CA (1) CA3046558A1 (en)
CL (1) CL2019001685A1 (en)
CO (1) CO2019006292A2 (en)
CU (1) CU20190057A7 (en)
EC (1) ECSP19043725A (en)
IL (1) IL267210A (en)
JO (1) JOP20190147A1 (en)
MA (1) MA50763A (en)
MX (1) MX2019007352A (en)
PE (1) PE20191206A1 (en)
PH (1) PH12019501339A1 (en)
TW (1) TWI780096B (en)
WO (1) WO2018118957A1 (en)
ZA (1) ZA201903581B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (en) 2016-12-19 2019-06-18 Axcella Health Inc Amino acid compositions and methods for the treatment of liver diseases
EP3615018A1 (en) 2017-04-28 2020-03-04 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
CN111295187A (en) 2017-08-14 2020-06-16 胺细拉健康公司 Amino acid composition for treating liver diseases
MX2020001766A (en) * 2017-08-14 2020-07-29 Axcella Health Inc Branched-chain amino acids for the treatment of neuronal injury.
CU20200106A7 (en) 2018-06-20 2021-08-06 Axcella Health Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASEMIAS
WO2019246310A1 (en) * 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the reduction or treatment of inflammation
US11679089B2 (en) 2018-06-20 2023-06-20 Axcella Health Inc. Methods of manufacturing amino acid compositions
MA52971A (en) 2018-06-20 2021-04-28 Axcella Health Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAT INFILTRATION IN THE MUSCLE
CN112752575A (en) * 2018-09-27 2021-05-04 雀巢产品有限公司 Use of histidine, glycine and other amino acids for the prevention of insulin resistance and/or diabetes
WO2020245299A1 (en) 2019-06-07 2020-12-10 Société des Produits Nestlé S.A. Compositions and methods using one or more autophagy-inducing amino acids to potentiate musculoskeletal effect of one or more anabolic amino acids
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
KR102456270B1 (en) * 2019-09-24 2022-10-19 마이오텍사이언스 주식회사 Pharmaceutical composition for preventing or treating sarcopenia comprising non-natural amino acids derivatives
KR102338447B1 (en) * 2019-09-24 2021-12-14 마이오텍사이언스 주식회사 Pharmaceutical composition for preventing or treating sarcopenia comprising non-natural amino acids
US20220331290A1 (en) * 2019-09-24 2022-10-20 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia, containing unnatural amino acid
CN110801007A (en) * 2019-12-17 2020-02-18 苟春虎 Nutritional peptide for sarcopenia of old people
US20230089723A1 (en) * 2020-03-06 2023-03-23 Axcella Health Inc. Amino acid compositions and methods for muscle and myotube modulation
KR102802853B1 (en) * 2021-02-26 2025-05-07 이엑스헬스케어 주식회사 Composition having the effect of inhibiting muscle loss or promoting muscle regeneration through skin-derived exosomes
CN113288890B (en) * 2021-06-21 2022-02-22 南方医科大学南方医院 Application of N-acetyl-L-cysteine in preparation of medicine for preventing and/or treating sports injury
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid
WO2025167857A1 (en) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 Method and composition for enhancing or improving muscle function and/or improving athletic performance and/or preventing or alleviating fatigue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020090214A (en) * 2000-02-01 2002-11-30 머슬테크 리서치 앤드 디벨롭먼트, 인크. αLIPOIC ACID BASED FOOD SUPPLEMENT FOR INCREASING LEAN MUSCLE MASS AND STRENGTH
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
WO2006105112A2 (en) * 2005-03-29 2006-10-05 Ajinomoto Co., Inc. Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
JP2007023921A (en) * 2005-07-19 2007-02-01 Toyota Motor Corp Control device for internal combustion engine
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
CN100518815C (en) * 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 Composition of amino acid
MX2014001996A (en) * 2011-08-19 2014-08-29 Musclepharm Corp Compositions and methods for use in promoting lean body mass.
WO2015061607A1 (en) * 2013-10-23 2015-04-30 Whitehead Institute For Biomedical Research Mtorc1 modulation by amino acids and uses thereof

Also Published As

Publication number Publication date
BR112019012476A2 (en) 2020-04-14
ZA201903581B (en) 2020-12-23
PE20191206A1 (en) 2019-09-10
JOP20190147A1 (en) 2019-06-18
CO2019006292A2 (en) 2019-06-28
US20180169047A1 (en) 2018-06-21
ECSP19043725A (en) 2019-07-31
CL2019001685A1 (en) 2019-08-30
EP3554493A1 (en) 2019-10-23
KR20190099243A (en) 2019-08-26
CN110267655A (en) 2019-09-20
PH12019501339A1 (en) 2019-09-30
WO2018118957A1 (en) 2018-06-28
IL267210A (en) 2019-08-29
TWI780096B (en) 2022-10-11
US20180207119A1 (en) 2018-07-26
CU20190057A7 (en) 2020-02-04
MA50763A (en) 2019-10-23
AU2017379825A1 (en) 2019-06-13
US20180169046A1 (en) 2018-06-21
CA3046558A1 (en) 2018-06-28
TW201827068A (en) 2018-08-01
JP2020502183A (en) 2020-01-23

Similar Documents

Publication Publication Date Title
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12017500746A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
ECSP20011578A (en) AMINO ACID COMPOSITIONS FOR THE TREATMENT OF LIVER DISEASE
MX2017005834A (en) Aadc polynucleotides for the treatment of parkinson's disease.
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA201992607A1 (en) SOLID FORMS OF UBERODESOXYCHOLATE BERBERIN, THEIR COMPOSITIONS AND METHODS
MD20160007A2 (en) Heterobicycloaryl RORC2 inhibitors and methods of use thereof
EA201691567A1 (en) METHODS OF TREATING PULMONARY INJURIES TO THE BRAIN
PH12018501443A1 (en) Methods of administering hepcidin
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
MX2020001428A (en) Compositions of grapiprant and methods for using the same.
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
MX2019004179A (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease.
PH12019501358A1 (en) Methods of administering hepcidin
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
EA201991504A1 (en) COMPOSITIONS BASED ON AMINO ACIDS AND METHODS FOR TREATING DISEASES AND DISORDERS OF MUSCLES
EA201592012A8 (en) APPLICATION OF FLAGELLIN FOR IMPROVED CHEMOTHERAPY
HK40013671A (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
IN2013MU03429A (en)